RedHill Biopharma (RDHL, $0.17) announces positive data of Phase 2 study of RHB-107 for COVID-19
RedHill Biopharma Ltd announced positive observations from a Phase 2 study of RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the peer-reviewed International Journal of Infectious Diseases.
According to the results, there was a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 treated group versus 15% (3/20) hospitalized on the placebo group. It also revealed an approximate 88% reduction in reported new severe COVID-19 symptoms after treatment was initiated, with just 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled group reporting new severe COVID-19 symptoms. Further investigation suggested a median of 3 days to recovery from severe COVID-19 symptoms with upamostat – much faster compared to eight days with placebo.
RDHL's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for RDHL moved out of oversold territory on February 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In of the 46 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for RDHL just turned positive on March 03, 2026. Looking at past instances where RDHL's MACD turned positive, the stock continued to rise in of 31 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RDHL advanced for three days, in of 207 cases, the price rose further within the following month. The odds of a continued upward trend are .
RDHL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on February 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RDHL as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
RDHL moved below its 50-day moving average on February 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RDHL crossed bearishly below the 50-day moving average on February 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDHL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for RDHL entered a downward trend on March 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (78.125) is normal, around the industry mean (25.870). P/E Ratio (0.086) is within average values for comparable stocks, (74.862). RDHL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.017). RDHL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (0.150) is also within normal values, averaging (113.396).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RDHL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RDHL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in acquisition and development of patented formulations
Industry PharmaceuticalsGeneric
Advertisement